RxDoctor Payments Data

Craig Cieciura, MD

Internal Medicine · Carmel, INNPI 1265406458

Payments from drug & device makers

$854in general payments, 2019–2025

Across 57 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$201
  • AstraZeneca$138
  • Amarin Pharma, Inc.$53
  • Abbott$49
  • GSK$48
  • Pfizer$45
  • plus $320 from 16 others

What the payments were for

  • Food & beverage$854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$854 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$179,536
Medicare patients
455
Services billed
2,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide110$146,246
EliquisApixaban128$129,042
TrulicityDulaglutide66$76,340
JardianceEmpagliflozin43$63,033
XareltoRivaroxaban51$54,655
OzempicSemaglutide43$49,863
JanuviaSitagliptin Phosphate33$41,058
EntrestoSacubitril/Valsartan29$33,539
VascepaIcosapent Ethyl23$16,306
Tresiba Flextouch U-100Insulin Degludec15$14,513
Janumet XrSitagliptin Phos/Metformin Hcl19$13,611
SynthroidLevothyroxine Sodium100$9,974
VyvanseLisdexamfetamine Dimesylate17$9,712
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,807
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$8,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$25$222,586176 claims
PfizerEliquis, Paxlovid$45$134,759155 claims
MerckJanuvia, Janumet Xr$11$54,66952 claims
Johnson & JohnsonXarelto$15$54,65551 claims
Novo NordiskOzempic$201$49,86343 claims
NovartisEntresto$15$33,53929 claims
GSKAnoro Ellipta, Arnuity Ellipta$48$14,75832 claims
AbbVieSynthroid$42$9,974100 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$12$9,71217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →